NCT00053248View on ClinicalTrials.gov

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Leukemia
Interventions
DRUG

arsenic trioxide

DRUG

imatinib mesylate

Trial Locations (3)

33612

H. Lee Moffitt Cancer Center, Tampa

90095

UCLA Department of Medicine, Division of Hematology/Oncology, Los Angeles

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER

NCT00053248 - Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter